Novartis Sees Real Value Of Ofatumumab In MS, Pays GSK Up To $1Bn

GlaxoSmithKline is divesting its rights in ofatumumab in autoimmune indications, including multiple sclerosis, to Novartis. Novartis previously acquired the oncology rights for ofatumumab (marketed as Arzerra) as part of the major three-part transaction between the companies. It now holds complete rights to the fully human CD20-targeting monoclonal antibody.